ISPOR 21ST ANNUAL INTERNATIONAL MEETING

May 21-25, 2016 | Washington Hilton | Washington, DC, USA

EARLY REGISTRATION DEADLINE: APRIL 12, 2016

PROGRAM

Value, Affordability, and Patient Centeredness: Can We Have it All?

Join colleagues and hear from renowned experts in the HEOR field!

ISPOR is recognized globally as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in health care decisions.

- **Learn** new and novel applications in the conduct and use of HEOR.
- **Engage** with renowned experts in the field.
- **Network** with colleagues, collaborators, and clients.
- **Share** research, ideas, and developments in an open objective environment.
- **Advance** your career by participating in the ISPOR Short Course Program.
- **Stay current** on HEOR regulatory and policy issues.

What do ISPOR meetings offer?

ISPOR meetings are forums for discussion and dissemination of information surrounding HEOR. The meetings bring together experts and rising stars in the HEOR field to discuss the latest on research methods, real world data, health care policy, and patient centered outcomes. Held in an election year in the nation's capital, ISPOR DC will examine drug development, regulatory issues, and decision making through the lens of *Value, Affordability, and Patient Centeredness.*

Who Attends ISPOR meetings?

The ISPOR scope and sphere of influence comprises the international HEOR community: global leaders, policy makers, regulators, researchers, academicians, payers, decision makers, patients, and patient groups. This multi-stakeholder group is invested in using science and research to make better health care decisions.

Last year's ISPOR 20th Annual International Meeting hosted 3,700+ attendees from 78 countries, and facilitated more than 1,750 presentations!

ISPOR DC

Trending topics :

Real World Evidence ▪ Comparative Effectiveness ▪ Clinical Outcomes Assessment (COAs) ▪ Patient Preferences and Engagement ▪ Modeling ▪ Economic Evaluation ▪ Use of Health Policy in Decision Making ▪ Rare Disease ▪ Personalized Medicine ▪ Medical Devices ▪ Oncology ▪ Vaccines ▪ Medication Adherence ▪ Pricing & Reimbursement ▪ Budget Impact Studies ▪ Cost Effectiveness ▪ HTA

photo by John McGall

Make the most of ISPOR DC!

Networking

Connect with colleagues, collaborators, and/or clients!

- Continue session discussions with colleagues during the morning and afternoon coffee breaks.
- Chat over lunch in the Poster Hall.
- Explore exhibits and find products and services that meet your needs.
- Attend the Social Event on Tuesday evening to catch up with colleagues and create new connections.
- Connect with other attendees and schedule meetings via the ISPOR DC mobile app and web platform (available approximately one month prior to the meeting).

ISPOR Groups

Collaborate with members of your ISPOR groups during Invitational Meetings. Members worldwide actively participate in ISPOR Working Groups to advance global health outcomes research and the use of this research in health care decisions. ISPOR groups bring together different stakeholders interested in a topic to develop an ISPOR consensus knowledge product, such as a Special Interest Group article published in *Value in Health*.

Students

Network with student members worldwide! Join us at the Student Research Competition, Student and Faculty Icebreaker Reception, Student Research Showcase, Student Forum, and Student Mock Interviews – all highly attended events!

If you are interested in starting a Student Chapter at your University, see http://www.ispor.org/student/howtoform.asp for more information.

Exhibits

Explore exhibits and connect with organizations that provide relevant professional services, products, job opportunities, and more! Be sure to explore exhibitor virtual booths via the ISPOR website (http://www.ispor.org/Event/Exhibitors/2016Washington) and the ISPOR DC mobile app and web platform (available approximately one month prior to the meeting).

ISPOR would like to thank the current sponsors of the ISPOR 21st Annual International Meeting:

(Sponsors as of January 2016)

- Platinum Level:
Evidera, Pharmerit, Quintiles, and STATinMED Research
- Gold Level:
Mapi, Precision for Value, and Xcenda
- Silver Level:
Analysis Group, BaseCase Management GmbH, Corporate Translations, Covance Inc., Kantar Health, and RTI Health Solutions
- Bronze Level:
Pharmaceutical Health Services Research

Interested in becoming an Event Sponsor?
See www.ispor.org/Event/SponsorshipOpportunities/2016Washington



Plenary Sessions Featured at ISPOR DC

First Plenary Session:
Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk?

We have witnessed remarkable policy efforts geared toward shortening the timeline to bring medical products to patients in need. Legislative proposals aimed at accelerating the development of biopharmaceutical and other medical products have had bipartisan backing, as well as support from various stakeholder groups. However, these efforts have also drawn fire from opponents concerned they may circumvent patient safety. In this session, we will hear alternate views on accelerated development efforts, as well as the patient view on this issue. Speakers will summarize where we are globally on accelerating cures, highlight outstanding issues and questions being debated, and discuss where we are headed in terms of future proposals.

Moderator: Eleanor M. Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Speakers: Jerry Avorn, MD, Professor of Medicine, Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; **Scott Gottlieb, MD**, Resident Fellow, American Enterprise Institute, Washington, DC, USA; **Patricia Furlong**, Founding President & Chief Executive Officer, Parent Project Muscular Dystrophy (PPMD), Middletown, OH, USA

Second Plenary Session:
Making Medical Decisions in an Irrational World

Frameworks such as decision- and cost-effectiveness analyses to guide resource allocation options are grounded in neo-classical economic theory based on rational choice under uncertainty. Over the past four decades, there is increasing biologic and experimental evidence suggesting that these underpinnings are inconsistent with human preferences and behaviors. This session will present emerging behavioral economic models and findings and discuss how they will influence the design of health plans and methods for incorporating preferences.

Moderator: Bradley C. Martin, PharmD, RPh, PhD, Professor & Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Speakers: Kevin Volpp, MD, PhD, Staff Physician, Philadelphia VA Medical Center, Director, Center for Health Incentives and Behavioral Economics, Leonard Davis Institute, Vice Chairman, Health Policy, Medical Ethics and Health Policy, and Professor of Medicine and Health Care Management, Perelman School of Medicine and Wharton School, University of Pennsylvania, Philadelphia, PA, USA; **Douglas E. Hough, PhD**, Associate Scientist & Associate Director, Master of Healthcare Administration Program, Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; **Anthony Culyer, Hon DEcon, Hon FRCP, FRSA, FMedSci**, Emeritus Professor of Economics, University of York, York, UK and Adjunct Professor, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

Third Plenary Session:
PDUFA VI – Impact on Health Outcomes Research and Dissemination

The Prescription Drug User Fee Act (PDUFA) was first enacted in 1992 to expedite the drug approval process and must be reauthorized every five years. Congress and interested parties are negotiating the elements of the reauthorization that is expected to pass in 2016. This session will provide insights from the Food and Drug Administration, the pharmaceutical industry, and academics on the issues and examine the projected impact this legislation will have on health outcomes studies and the dissemination of this information to health care decision makers. **Moderator: Daniel Malone, PhD, RPh**, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

Speakers: Theresa M. Mullin, PhD, Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA; **Marc M. Boutin, JD**, Chief Executive Officer, National Health Council, Washington, DC, USA; **Sascha Haverfield, PhD, MSc**, Vice President, Scientific and Regulatory Affairs, PhRMA, Washington, DC, USA (invited)

Meeting Program Committee

ISPOR thanks the Meeting Program Committee for its contributions in developing the scientific community's leading HEOR program.

Program Committee Co-Chairs

Bradley C. Martin, PharmD, RPh, PhD, Professor & Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Eleanor M. Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Research Review Committee Co-Chairs

Rajender R. Aparasu, PhD, Professor & Department Chair, University of Houston, Houston, TX, USA

Carl V. Asche, MBA, MSc, PhD, Research Professor of Medicine & Director, Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

Laura T. Pizzi, PharmD, MPH, Professor, Thomas Jefferson University, Philadelphia, PA, USA

Patrick W. Sullivan, PhD, Professor, Regis University School of Pharmacy, Denver, CO, USA

Issue Panel Review Committee Co-Chairs

Chris Leibman, MS, PharmD, Vice President, HEOR – Global Market Access, Biogen, Cambridge, MA, USA

Newell McElwee, Associate Vice President, CORE, Merck and Co., Inc., North Wales, PA, USA

Brian O'Rourke, PharmD, President & Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

Workshop Review Committee Co-Chairs

Benjamin M. Craig, PhD, Associate Member, Department of Health Outcomes and Behavior, Moffitt Cancer Center and Associate Professor of Economics at the University of South Florida, Tampa, FL, USA

Sachin Kamal-Bahl, PhD, Vice President & Head, Global Health & Value Innovation Center, Pfizer, Inc., Philadelphia, PA, USA

Shelby D. Reed, PhD, RPh, Professor, Department of Medicine, Center for Clinical and Genetic Economics, Duke Clinical Research Institute and Member, Duke Cancer Institute, Durham, NC, USA

photo by Antonella Bozzini

Pre-Meeting Short Course Program

The ISPOR Short Course Program, offered in conjunction with ISPOR meetings around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge and technique in seven key topic areas ("Tracks") related to health economics and outcomes research. Short courses range in level from Introductory to Advanced and are taught by leading experts in the field, many with hands-on training opportunities!

Separate Short Course registration is required!



Short Courses are offered Saturday, May 21 and Sunday, May 22 in the topic areas:

Economic Methods
- Introduction to Pharmacoeconomics
- Cost-Effectiveness Analysis alongside Clinical Trials
- Statistical Methods in Economic Evaluations
- Budget Impact Analysis I: A 6-Step Approach
- Budget Impact Analysis II: Applications

Modeling Methods
- Bayesian Analysis – Overview and Applications
- Introduction to Modeling Methods
- Modeling: Design and Structure of a Model
- Value of Information and Probabilistic Analyses
- Discrete Event Simulation for Economic Analyses – Concepts
- Discrete Event Simulation for Economic Analyses – Applications
- Advanced Topics in Decision Analytic Modeling
- Advanced Decision Modeling for Health Economic Evaluations

Observational Data Methods
- Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources
- Use of Propensity Scores in Observational Studies of Treatment Effects
- Applications in Using Large Databases
- Use of Instrumental Variables in Observational Studies of Treatment Effects
- Introduction to Big Data Analysis: Graph Analytics

Outcomes Research Methods
- Meta-Analysis and systematic Reviews in Comparative Effectiveness Research
- Network Meta-Analysis

Patient Preference Methods
- Introduction to Conjoint Analysis
- Utility Measures

Patient-Reported Outcomes Methods
- Introduction to Patient-Reported Outcomes
- Advanced Patient-Reported Outcomes
- Patient-Reported Outcomes - Item Response Theory

Use of PE/OR Information
- Informatics and Interoperability: Speaking the Same Language
- Elements of Pharmaceutical/Biotech Pricing I - Introduction
- Case Studies in Pharmaceutical/Biotech Pricing II - Advanced
- Risk-Sharing/Performance-Based Arrangements for Drugs and other Medical Products
- Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

Select courses require use of your personal laptop.

Short Course Registration Information

Early Registration Deadline: April 12, 2016

All Day Courses 8:00am-5:00pm

Thru April 12, 2016
Standard fee: $700
Clinical/Government/Academia fee: $500
Student fee: $150

After April 12, 2016
Standard fee: $800
Clinical/Government/Academia fee: $600
Student fee: $200

Morning Courses 8:00am-12:00pm

Thru April 12, 2016
Standard fee: $350
Clinical/Government/Academia fee: $250
Student fee: $75

After April 12, 2016
Standard fee: $400
Clinical/Government/Academia fee: $300
Student fee: $100

Afternoon Courses 1:00-5:00pm

Thru April 12, 2016
Standard fee: $350
Clinical/Government/Academia fee: $250
Student fee: $75

After April 12, 2016
Standard fee: $400
Clinical/Government/Academia fee: $300
Student fee: $100

Short Course Continuing Education Accreditation (CPE & CME)

$100

>> See **www.ispor.org/Event/ShortCourses/2016Washington** for Short Course schedule and descriptions, as well as to register.

photo by John McGall

ISPOR 21st International Meeting Program

ISPOR DC features three thought-provoking plenary sessions and more than 1,850 presentations in the form of workshops, issue panels, forums, symposia, podium presentations, and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real world data, and clinical, economic, and patient-reported outcomes.

Meeting registration is required!

Saturday, May 21

8:00AM-5:00PM SHORT COURSES

Sunday, May 22

8:00AM-5:00PM SHORT COURSES

5:15PM-6:15PM EDUCATIONAL SYMPOSIUM
Assessing the Value Assessments: Are They Getting It Right or Heading in the Wrong Direction? *(Sponsored by National Pharmaceutical Council (NPC))*

6:30PM-7:30PM EDUCATIONAL SYMPOSIUM
Oncology Therapies: Are We Really Increasing Value and Affordability While Keeping the Focus on Patient Care? *(Sponsored by ICON plc)*

6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION

8:30PM-9:30PM ISPOR STUDENT & FACULTY ADVISOR RECEPTION

Monday, May 23

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM
Challenges and Opportunities in Value-Based Cancer Care: Assessing the Multi-Dimensional Influence of Value Assessment and Standardized Value Algorithms on Treatment Choice from Clinical, Policy, and HEOR Viewpoints *(Sponsored by Cardinal Health)*

8:30AM-2:15PM POSTERS – SESSION I

8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION
Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk? *See page 3*

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS – SESSION I

11:00AM-12:00PM ISSUE PANELS – SESSION I
IP1: Payers' Use of Independent Reports in Decision Making – Will There Be an ICER Effect?
IP2: Are We Ready for a Cure? Key Value Demonstration and Policy Considerations for the New Wave of Potentially Curative Therapies
IP3: What's Next for Value Frameworks for Prescription Drugs?
IP4: Performance-Based Risk-Sharing Arrangements: What Are the Views from the Negotiating Table?
IP5: Use of Real-World Evidence in Payer Decision Making: Fact or Fiction?

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – SESSION I

12:15PM-1:15PM EDUCATIONAL SYMPOSIUM
How Real-World Evidence (RWE) Can Enable Pharma to Partner in Health Care Delivery *(Sponsored by IMS Health)*

12:15PM-1:15PM ISPOR STUDENT RESEARCH SHOWCASE

1:15PM-2:15PM POSTER AUTHOR DISCUSSION – SESSION I

2:15PM-3:15PM PODIUMS – SESSION I
Budget Impact Studies | Cardiovascular Outcomes Studies | Comparative Effectiveness Research | Medication Use Research | Prescription Pricing Studies | Systemic Disorders Studies

3:15PM-3:45PM BREAK & EXHIBITS

3:45PM-4:45PM PODIUMS – SESSION II
Cancer Outcomes Studies | Cost-Effectiveness Research | Endocrine Disorders Studies | Health Care Expenditure Studies | Medication Adherence Studies | Patient Preference Studies

3:45PM-7:45PM POSTERS – SESSION II

5:00PM-6:00PM WORKSHOPS – SESSION I
W1: Promoting the Safe Use of Medications and Enhancing Understanding of Stakeholders' Opinions
W2: Risk-Sharing Agreements for Manufacturers and Commercial Payers in the United States: How Can Theory Help Practice? Design and Aligning Incentives Are Key
W3: Biosimilars: Current Developments and Real-World Evidence Generation
W4: The Science and Art of Performing Network Meta-Analyses (NMA) to Aid Decision Making for Type 2 Diabetes Treatment: How Does It Work in Practice?
W5: Constrained Optimization: Why Making Pizza and Maximizing Health Care Value Are the Same Problem
W6: Equivalence of Paper and Electronic Modes of Patient-Reported Outcome Data Collection: An Answered Question?
W7: Exploring and Leveraging Known Resources to Support Pediatric Clinical Outcomes Assessment (COA) Development

6:00PM-7:45PM EXHIBITORS' OPEN HOUSE RECEPTION & POSTERS – SESSION II

6:15PM-7:15PM ISPOR FORUMS – SESSION I
F1: Issues to Address in Revising the ISPOR Code of Ethics
F2: Clinical Outcomes Assessment (COA) Measurement in Rare Disease Clinical Trials – A Case Study on Application of Emerging Good Practices
F3: Statistical Analysis of Discrete-Choice Experiments: A Discussion of the ISPOR Conjoint Analysis Good Research Practices Task Force Report
F4: Economic Evaluation of Vaccines
F5: Fit for Purpose: Preparing for a Professional Career
F6: Patient-Centered Health Care in the BRICS Countries
F7: Moving Towards an Integral Approach to Patients with Rare Diseases: An International Perspective

6:45PM-7:45PM POSTER AUTHOR DISCUSSION – SESSION II

7:30PM-9:00PM ISPOR LATIN AMERICA CONSORTIUM WELCOME RECEPTION

7:30PM-9:00PM ISPOR ASIA CONSORTIUM WELCOME RECEPTION

7:30PM-9:00PM ISPOR ARABIC NETWORK AND AFRICA NETWORK WELCOME RECEPTION

** Program subject to change*

ISPOR 21st International Meeting Program

Early Registration Deadline: April 12, 2016

Tuesday, May 24

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM
Big Data, Clinical Evidence and Health Plan Reality: Drivers of Effectiveness in the Real World *(Sponsored by LASER ANALYTICA)*

8:30AM-2:15PM POSTERS – SESSION III

8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION
Making Medical Decisions in an Irrational World *See page 3*

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS – SESSION III

11:00AM-12:00PM ISSUE PANELS – SESSION II
IP6: Multi-Indication Pricing: Do We Want It? Can We Operationalize It?

IP7: Pharmaceutical Pricing in the United States: Are We Balancing Innovation and Affordability?

IP8: Incorporating Real-World Evidence for Regulatory Decision Making: Is the Device Ecosystem Ready?

IP9: Next Generation Comparative Effectiveness Research – Are We Getting Organized to Facilitate Research for the Individual Patient?

IP10: Cost-Effectiveness Thresholds: Should We Be Generating More Empirical Evidence and, If So, How?

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – SESSION III

12:15PM-1:15PM EDUCATIONAL SYMPOSIUM
Value-Based Contracting for Pharmaceuticals: Driving Value and Quality of Care *(Sponsored by Optum)*

1:15PM-2:00PM ISPOR GENERAL BUSINESS MEETING

1:15PM-2:15PM POSTER AUTHOR DISCUSSION – SESSION III

2:15PM-3:15PM ISSUE PANELS – SESSION III
IP11: How Do Culture, Values, and Institutional Context Shape the Methods and Use of Economic Evaluation?

IP12: Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?

IP13: Precision Medicine: The End of Outcomes Research?

IP14: The Value of Specialty Drugs: Can We Develop Novel Access Policies for Novel Medicines?

IP15: Social Listening for Safety Outcomes and Pharmacoeconomic Considerations: Has the Time Come?

3:15PM-3:45PM BREAK & EXHIBITS

3:45PM-4:45PM WORKSHOPS – SESSION II
W8: Establishing the Value of Diagnostic and Prognostic Tools in Health Technology Assessment

W9: Five Years of Health Care Horizon Scanning for AHRQ – Results and Lessons Learned

W10: Real-World Data and Real-World Evidence in Latin America: It Takes Two to Tango

W11: Specialty Drugs Require Specialty Methods: Maximizing the Value of Administrative Claims for Specialty Drug Outcomes & Policy Research

W12: Innovative Clinical Trials Designs for Rigorous Testing of Treatment Outcomes for Rare Diseases, Pilot Studies, and Conversion of Efficacy to Effectiveness Estimates

W13: Patients as Partners in Research – Making It a Reality

W14: Choice Defines Value: Patient Preferences and Multi-Criteria Decision Analysis Are Key for any Evidence-Based Appraisal Process in Health Technology Assessment

3:45PM-7:45PM POSTERS – SESSION IV

5:00PM-6:00PM WORKSHOPS – SESSION III
W15: Is Value Truly in the Eye of the Beholder? Analyzing the Heterogeneity of Outputs from ASCO, NCCN and DrugAbacus Oncology Value Frameworks and Exploring Implications for Cancer Drug Development

W16: Visualizing Data for Hypothesis Generation Using Large-Volume Health Care Claims Data

W17: Medical Device Evaluations Via Coordinated Registry Networks: Analytical and Infrastructure Considerations

W18: Predicting Market Outlook: Enhancing Market Forecasting Via Application of Pharmacoeconomic Modeling Techniques

W19: Patient-Centered Benefit-Risk Analysis: Regulatory Developments and Prospects

W20: A Framework for Measuring Multiple Medication Adherence

W21: Patients as Partners in the Development and Interpretation of Clinical Outcome Assessments: Methods, Challenges, and Benefits

6:00PM-7:45PM EXHIBITORS' WINE & CHEESE RECEPTION & POSTERS – SESSION IV

6:15PM-7:15PM ISPOR FORUMS – SESSION II
F8: Developing and Evaluating Clinician-Reported Outcomes (ClinROs) – A Case Study on Application of Emerging Good Practices

F9: The Do's and Don'ts of Performing a Scoping Review

F10: Use and Management of Big Data in Health Economics and Outcomes Research for Creating Best Practices in Asia-Pacific: Experiences and Lessons Learned in Australia, Japan, Singapore, South Korea, and Taiwan

F11: Public Engagement in Health Care Priority Setting: Experiences and Challenges at Engaging the Public and Measuring Public Preferences in Latin America

F12: Value in Health Forum on Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions

F13: Development and Application of Multi-Criteria Decision Analysis in Central & Eastern Europe (CEE) in Cooperation with Western Countries

F14: The Health and Economic Threats of Non-Communicable Diseases in the Middle East and North Africa

6:45PM-7:45PM POSTER AUTHOR DISCUSSION – SESSION IV

8:00PM-11:30PM ISPOR SOCIAL EVENT
Featuring the ISPOR Monte Carlos!

** Program subject to change*

ISPOR 21st International Meeting Program

Wednesday, May 25

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM

8:30AM-2:45PM POSTERS – SESSION V

8:30AM-9:30AM ISSUE PANELS – SESSION IV

IP16: Are Alternative Financing Approaches Needed for Innovative Therapies?

IP17: Harnessing Big Data for Wound Healing Research: Which is More Relevant in the Quest for Evidence – Real-World Patient-Centered Outcomes or Randomized Trials?

IP18: Creating and Analyzing Symptom Endpoints When There is Symptom Heterogeneity across Patients: What Are the Potential Solutions?

IP19: Assessing the Value of Medical Devices – Choosing the Best Path Forward: Where Do We Go from Here?

IP20: What is the Value of Value Frameworks to Patients? The Case in Oncology

9:30AM-9:45AM BREAK, EXHIBITS & POSTERS – SESSION V

9:45AM-11:00AM WELCOME & THIRD PLENARY SESSION

PDUFA VI – Impact on Health Outcomes Research and Dissemination *See page 3*

11:00AM-11:30AM ISPOR 21st INTERNATIONAL MEETING RESEARCH PRESENTATION AWARDS

11:30AM-1:45PM LUNCH, EXHIBITS & POSTERS – SESSION V

11:45AM-12:45PM EDUCATIONAL SYMPOSIUM

12:45PM-1:45PM POSTER AUTHOR DISCUSSION HOUR – SESSION V

1:45PM-2:45PM WORKSHOPS – SESSION IV

W22: The Opportunity for Using Patient-Centric, Comparative Effectiveness, and Outcomes Research Data: Evolving Approaches to Drug Pricing and Reimbursement in the United States

W23: Methodologies for Evaluating Geospatial Access in Medication Use Studies

W24: Missing Data in Observational Studies

W25: Survival Curves with Non-Randomized Designs: How to Address Potential Bias and Interpret Adjusted Survival Curves

W26: Empowering Patient Populations with Physical or Cognitive Limitations through Electronic Clinical Outcome Assessments (eCOAs)

2:45PM-3:00PM BREAK & EXHIBITS – SESSION V

3:00PM-4:00PM WORKSHOPS – SESSION V

W27: Communication and Outcomes: Implementing a Multi-Stakeholder Communimetric System in a Behavioral Health Setting

W28: We're Five Years in…Has Electronic Health Records (EHR) Data Met Our Expectations? Successes and Challenges When Using Integrated Administrative Claims and EHR Data to Generate Economic Evidence, Manage Population Health, and Evaluate Comparative Effective

W29: The Health Economics and Outcomes Research Applications and Valuation of Digital Health Technologies and Machine Learning

W30: Secondary Analysis of Qualitative Data to Inform the Development of Patient-Reported Outcome (PRO) Instruments

W31: Some New Strategies for Eliciting and Modeling Utility Values of Multi-Attribute Health States

Venue Information: The ISPOR 21st Annual International Meeting will be held at the Washington Hilton (1919 Connecticut Ave., NW, Washington, DC 20009), located approximately 8 miles (12km) from the Ronald Reagan Washington National Airport and within 10 minutes walking distance of Dupont Circle.

Meeting Registration Fees

Early Registration Deadline: April 12, 2016

Standard

Thru April 12, 2016
Member $750 / Non-Member $900

After April 12, 2016
Member $850 / Non-Member $1000

Clinical Practitioners (Clinical Practice, Hospital)

Thru April 12, 2016
Member $550 / Non-Member $700

After April 12, 2016
Member $650 / Non-Member $800

Full-Time Government and Academia

Thru April 12, 2016
Member $450 / Non-Member $600

After April 12, 2016
Member $550 / Non-Member $700

Patient Representative

Thru April 12, 2016
Member $150 / Non-Member $300

After April 12, 2016
Member $200 / Non-Member $350

Full-Time Students

(must provide current enrollment docs)
Thru April 12, 2016
Member $150 / Non-Member $185

After April 12, 2016
Member $200 / Non-Member $235

One Day Registration (per day)

May 23, May 24, or May 25
Thru April 12, 2016
Member $400 / Non-Member $550

After April 12, 2016
Member $400 / Non-Member $550

ISPOR Social Event:

Tuesday, May 24, 8:00PM-11:30PM
Member/Non-member $65
Student $30

>> See **www.ispor.org/Event/Index/2016Washington** for full program information and to register.

** Program subject to change*